| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2014: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
|---|
| Outline of Final Research Achievements |
For optimum VEGF antibody administration, we aimed to develop a tailor-made treatment. This purpose included the optimization of the method of administration and examination of VEGF-stimulating factor. We analyzed RPE, which was stressed by hypoxic culture and low glucose, to find possible VEGF expression enhancing factors this year. From the results of proteomic analysis, the known-gene was presumed to be important, we analyzed the factors by additional real-time PCR and Western blotting. Expression of VEGF was confirmed to be suppressed with the resulting siRNA. Since gene KO mice of this factor was found to have been made, we performed an individual preparation of the mice. We initiated photocoagulation induced neovascularization model studies currently.
|
